GlassScriptPhysician profile
Caroline Elizabeth Morris
NPI 1497306575
$9,113.42
in general payments reported to CMS, 2019-2025
30 companies · $1,747 in 2025
The $1,747 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,750 · 2022: $1,798 · 2023: $1,889 · 2024: $1,928 · 2025: $1,747.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,565.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,564.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,466.55 | 2021-2025 | |
| Novo Nordisk INC | $927.30 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $908.86 | 2021-2025 | Evenity, Repatha, Otezla |
| Glaxosmithkline, LLC. | $854.28 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $829.73 | 2021-2025 | Xifaxan |
| Lilly USA, LLC | $802.04 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $700.77 | 2021-2025 | Farxiga, Breztri, Nexium |
| Boehringer Ingelheim Pharmaceuticals, INC. | $445.41 | 2021-2024 | Jardiance, Stiolto Respimat, Tradjenta |
| Pfizer INC. | $357.71 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $310.26 | 2021-2025 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $258.89 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $165.89 | 2022-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $165.00 | 2023-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $130.48 | 2025 | Fanapt |
| Merck Sharp & Dohme LLC | $129.46 | 2021-2023 | Steglatro, Belsomra |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $124.99 | 2021-2022 | |
| Ardelyx, INC. | $101.31 | 2024-2025 | Ibsrela |
| Mylan Specialty L.P. | $64.15 | 2022-2023 | Yupelri |
| Exact Sciences Corporation | $63.86 | 2023-2024 | Cologuard Collection Kit |
| Viatris Specialty LLC | $58.58 | 2025 | Yupelri |
| Astellas Pharma US INC | $39.86 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $38.41 | 2024 | Rexulti |
| Amarin Pharma, INC. | $37.28 | 2021 | |
| Idorsia Pharmaceuticals US INC | $35.78 | 2023 | Quviviq |
| Phathom Pharmaceuticals, INC. | $18.22 | 2025 | Voquezna |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.16 | 2023 | Lifevest |
| Ironwood Pharmaceuticals, INC | $17.96 | 2021 | |
| Corcept Therapeutics | $15.57 | 2024 | Korlym |
| Hikma Pharmaceuticals USA | $13.49 | 2021 | |
| Axsome Therapeutics, INC. | $13.17 | 2024 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.